Literature DB >> 28791608

Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy.

Shin Lee1, Takahiro Yamauchi2, Norito Ishii3, Takashi Hashimoto4, Keiichi Kinoshita5, Shin Imamura5, Kenichi Kamiya5.   

Abstract

Paraneoplastic pemphigus (PNP) is a rare, fatal, paraneoplastic autoimmune mucocutaneous blistering disease, commonly associated with lymphoproliferative disorders, including malignant lymphomas. Lymphoproliferative disorders associated with PNP are sometimes associated with a serious lung complication, bronchiolitis obliterans (BO). Due to its rarity, guidelines for the management of PNP have not been established. Furthermore, most patients die within 1 year. Here we report the successful treatment of lymphoma-associated PNP and BO using R-CHOP chemotherapy. A 53-year-old Japanese man was admitted to our hospital for severe erosive stomatitis. Computed tomography and positron emission tomography showed multiple lymphadenopathies. He was diagnosed with follicular lymphoma (Ann Arbor stage IVA) and PNP-related BO. The patient underwent six cycles of R-CHOP and an additional cycle of rituximab. Both the erosive stomatitis and the obstructive lung disease persisted, but complete response of the follicular lymphoma was achieved. The patient survived 27 months after diagnosis. Although he died from progressive respiratory failure due to BO, we note that this patient achieved the longest survival of any reported case of PNP-related BO associated with a lymphoproliferative disorder. The present case suggests that intensive immunochemotherapy for underlying lymphoma may improve the prognosis in patients with PNP-related BO associated with lymphoma.

Entities:  

Keywords:  Bronchiolitis obliterans; Follicular lymphoma; Paraneoplastic pemphigus; R-CHOP

Mesh:

Substances:

Year:  2017        PMID: 28791608     DOI: 10.1007/s12185-017-2305-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  29 in total

1.  Severe breathlessness, mouth ulcers and skin blistering in a female.

Authors:  V S Gudi; A D Ormerod; J Weir; K M Kerr; G Devereux
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

Review 2.  Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome.

Authors:  Virendra N Sehgal; Govind Srivastava
Journal:  Int J Dermatol       Date:  2009-02       Impact factor: 2.736

3.  Prognostic factors of paraneoplastic pemphigus.

Authors:  Sandy Leger; Damien Picard; Saskia Ingen-Housz-Oro; Jean-Philippe Arnault; François Aubin; Francis Carsuzaa; Gilles Chaumentin; Jacqueline Chevrant-Breton; Olivier Chosidow; Béatrice Crickx; Michel D'incan; Michel Dandurand; Stéphane Debarbieux; Emmanuel Delaporte; Olivier Dereure; Marie-Sylvie Doutre; Gérard Guillet; Denis Jullien; Ingrid Kupfer; Jean-Philippe Lacour; Fabienne Leonard; Catherine Lok; Laurent Machet; Ludovic Martin; Carle Paul; Jean-Michel Pignon; Caroline Robert; Luc Thomas; Pierre-Jean Weiller; Vincent Ferranti; Danièle Gilbert; Philippe Courville; Estelle Houivet; Jacques Benichou; Pascal Joly
Journal:  Arch Dermatol       Date:  2012-10

4.  Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis.

Authors:  T Hashimoto; M Amagai; K Watanabe; T P Chorzelski; B S Bhogal; M M Black; H P Stevens; D M Boorsma; N J Korman; S Gamou
Journal:  J Invest Dermatol       Date:  1995-05       Impact factor: 8.551

5.  Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia.

Authors:  G J Anhalt; S C Kim; J R Stanley; N J Korman; D A Jabs; M Kory; H Izumi; H Ratrie; D Mutasim; L Ariss-Abdo
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

6.  Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus.

Authors:  P Joly; C Richard; D Gilbert; P Courville; O Chosidow; J C Roujeau; M Beylot-Barry; M D'incan; P Martel; P Lauret; F Tron
Journal:  J Am Acad Dermatol       Date:  2000-10       Impact factor: 11.527

7.  Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.

Authors:  V T Nguyen; A Ndoye; K D Bassler; L D Shultz; M C Shields; B S Ruben; R J Webber; M R Pittelkow; P J Lynch; S A Grando
Journal:  Arch Dermatol       Date:  2001-02

8.  Paraneoplastic Pemphigus and Bronchiolitis Obliterans in a Patient with Splenic B-cell Lymphoma.

Authors:  Shiou-Han Wang; Chia-Yu Chu; Hsuan-Hsiang Chen; Yih-Leong Chang; Kuan-Yu Chen; Hsien-Ching Chiu
Journal:  J Formos Med Assoc       Date:  2007-09       Impact factor: 3.282

9.  Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

Authors:  P Solal-Céligny; E Lepage; N Brousse; C L Tendler; P Brice; C Haïoun; J Gabarre; B Pignon; G Tertian; R Bouabdallah; J F Rossi; C Doyen; B Coiffier
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

Review 10.  False positive and false negative FDG-PET scans in various thoracic diseases.

Authors:  Jung Min Chang; Hyun Ju Lee; Jin Mo Goo; Ho-Young Lee; Jong Jin Lee; June-Key Chung; Jung-Gi Im
Journal:  Korean J Radiol       Date:  2006 Jan-Mar       Impact factor: 3.500

View more
  2 in total

Review 1.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 2.  Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.

Authors:  Roberto Maglie; Giovanni Genovese; Farzan Solimani; Alba Guglielmo; Alessandro Pileri; Francesca Portelli; Michael Hertl; Angelo Valerio Marzano; Emiliano Antiga
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.